iShares MSCI France ETF vs Viatris Inc — how do they compare? iShares MSCI France ETF trades at $45.16, while Viatris Inc trades at $16.6 (market cap $19.44B). The key difference: Viatris Inc pays a 2.88% dividend while iShares MSCI France ETF pays none, and Viatris Inc is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals.
| EWQ | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $17.39 |
52-Week Low | $41.43 | $8.74 |
Market Cap | — | $19.44B |
Enterprise Value | — | $31.65B |
Dividend Yield | — | 2.88% |
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI France ETF (EWQ) is trading at $45.16, up 0.27% on the day, while exhibiting a bearish technical signal with 11 sell signals versus 6 buy signals. The fund faces headwinds from European Central Bank rate hikes and energy market volatility driven by Middle East tensions, though it offers exposure to French technology investments and a scheduled $1.09 dividend in June 2026.
Outlook remains cautious amid macroeconomic uncertainty, with investment opportunity tied to France's €13 billion tech sovereignty push and AI investments, balanced against risks from energy price shocks, potential job losses in key EU sectors, and geopolitical trade tensions that could impact European equities.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Trailing returns across standard periods
Latest headlines on both assets
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →